• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

The Global Contraceptives Market to Garner a Value of US$ 37,242.7 Mn By 2025-End

Share:

February 21, 2022

Introduction Of New, Innovative, And Low-Cost Contraceptive To Significantly Leverage The Contraceptive Market

The Fact.MR market study on the contraceptive market provides deep dive into key developments in the Contraceptive market. The report offers a comprehensive analysis of leading segments in terms of product type, distribution type, key regions.

Fact.MR – A Market research and competitive intelligence provider: The global contraceptives market shall surpass a market valuation of US$ 37,242.7 Mn by the end of 2025. Demand for contraceptives to register a robust market size of 6.4% CAGR during the forecast period (2020-2025).

Most unwanted pregnancies occur among adolescents and young women in the puberty period. Such pregnancies are a major source of the regularity of sexually transmitted diseases (STDs) such as HIV, chlamydia, genital herpes, and hepatitis B.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Other trends, notably the introduction of new, innovative, and low-cost contraceptive devices by key market players are also expected to significantly leverage the contraceptive market.

For Critical Insights on This Market, Request for More Info

The COVID-19 pandemic is impassive to bring about a downturn in the sales of contraceptives, owing to social distancing and limited physical contact among young people. The global supply of external physical barriers such as condoms shall experience a drop, owing to tighter border restrictions regarding import and export of products and reduced production.

These include nausea, headache, weight gain, increased bleeding, dysmenorrhea, and menstrual changes. Moreover, the introduction of custom-fit condoms by key market players is expected to burgeon the segment’s market share.
The COVID-19 pandemic is poised to bring about a downturn in the sales of contraceptives, owing to social distancing and limited physical contact among young people.

Read more here

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Chicago Startup Level Ex Purchased By German Tech FirmChicago Startup Level Ex Purchased By German Tech Firm
  • AliveCor Teams up with Huami to Develop Medical-Grade WearablesAliveCor Teams up with Huami to Develop Medical-Grade Wearables
  • Cantel Expands its Life Sciences Portfolio through Acquisition of Stericycle’s Controlled Environmental Solutions BusinessCantel Expands its Life Sciences Portfolio through Acquisition of Stericycle’s Controlled Environmental Solutions Business
  • Augmedix Launches Tech-Enabled Service Within Emergency Departments to Provide Real-Time Support and Optimize Clinician WorkflowsAugmedix Launches Tech-Enabled Service Within Emergency Departments to Provide Real-Time Support and Optimize Clinician Workflows
  • COVID-19: Balancing Risk with RewardCOVID-19: Balancing Risk with Reward
  • Hims & Hers Looks to Brick-and-Mortar Care Through Carbon PartnershipHims & Hers Looks to Brick-and-Mortar Care Through Carbon Partnership
  • FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular LymphomaFDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
  • Neurotechnology Company Cognito Therapeutics Scores $73MNeurotechnology Company Cognito Therapeutics Scores $73M

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications